Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIC-101 + Nab-paclitaxel in Advanced Solid Tumors
NCT03928314Phase 1Terminated
- Sponsor
- ORIC Pharmaceuticals
- Start
- May 2019
- Primary completion
- Sep 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of ORIC-101 in solid tumor, pancreatic ductal adenocarcinoma (PDAC), ovarian cancer and 1 more (2 arms), sponsored by ORIC Pharmaceuticals. Primary endpoints: Recommended Phase 2 Dose at 12 months and Objective Response Rate at 18 months. Started May 2019; status: terminated.
02
Drugs
ORIC-101
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)ovarian cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03928314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03928314.